1 the two-drug combination of a 5-HT3 receptor serotonin antagonist and dexamethasone.

2 including a specified dose and schedule of a serotonin-antagonist and dexamethasone, were assigned to

3 ximately 55% by methysergide (broad spectrum serotonin antagonist) and potentiated ( approximately 16

4 e mechanism, such as prostacyclin analogues, serotonin antagonists, and calcitonin gene-related pepti

5 er the appropriate and cost-effective use of serotonin-antagonist antiemetic drugs spurred the creati

6 versally high concordance include the use of serotonin antagonist antiemetics according to the ASCO g

7 s (hematopoietic colony-stimulating factors, serotonin antagonist antiemetics, and taxanes), yielding

8                                              Serotonin antagonists are logical treatments but have ye

9 e three-drug combination of a 5-HT3 receptor serotonin antagonist, dexamethasone, and aprepitant is r

10 tment of cells with methiothepin mesylate, a serotonin antagonist, enhanced infection by reovirus.

11 trolled trials of newer antiemetics, such as serotonin antagonists like ondansetron, have demonstrate

12                             Furthermore, the serotonin antagonist mianserin blocked feeding-induced d

13 e sleep apnea, we studied the effects of two serotonin antagonists on upper airway dilator muscle act

14 n atypical antipsychotic with mixed dopamine/serotonin antagonist properties (clozapine).

15            Pretreatment with histamine-H1 or serotonin antagonists reduced Eo migration in response t

16 nin inhibited acetylcholine release, whereas serotonin antagonists stimulated release.

17          Alosetron is a potent and selective serotonin antagonist that recently became the first Food